Literature DB >> 18688087

Phosphorylated tau: toxic, protective, or none of the above.

Rudy J Castellani1, Akihiko Nunomura, Hyoung-gon Lee, George Perry, Mark A Smith.   

Abstract

Identification of phosphorylated tau as the major protein component of neurofibrillary tangles (NFTs) led to the concept that phosphorylated tau was inherently toxic and, as such, intimately involved in Alzheimer's disease (AD) pathogenesis. While superficially logical, this construct ignores a number of key findings in AD, including i) that NFTs are encountered in viable neurons until late stage disease; ii) that NFTs persist within the neuronal cytoplasm for decades; iii) that NFTs are encountered, sometimes in significant numbers, in cognitively intact elderly; and iv) that neurons with NFTs contain normal content and structure of microtubules. Experimental data in transgenic animal models has further demonstrated that NFTs accumulate in neurons in spite of tau suppression and behavior normalization. These data call into question the inherent toxicity of phosphorylated tau, seemingly leaving the only viable hypothesis of the ad hoc "toxic intermediate" phosphorylated tau concept. However, since we also know that phosphorylated tau sequesters redox active heavy metals and protects against oxidative stress, here we suggest that phosphorylated tau serves a protective role against cellular toxicity.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18688087      PMCID: PMC2765711          DOI: 10.3233/jad-2008-14404

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  60 in total

1.  Alzheimer's disease. New insights into its cause lead to new drug strategies.

Authors:  J M Nash
Journal:  Time       Date:  2001-01-15

Review 2.  Oxidative stress and neuronal adaptation in Alzheimer disease: the role of SAPK pathways.

Authors:  Xiongwei Zhu; Arun K Raina; Hyoung-Gon Lee; Mark Chao; Akihiko Nunomura; Massimo Tabaton; Robert B Petersen; George Perry; Mark A Smith
Journal:  Antioxid Redox Signal       Date:  2003-10       Impact factor: 8.401

3.  Differential activation of neuronal ERK, JNK/SAPK and p38 in Alzheimer disease: the 'two hit' hypothesis.

Authors:  X Zhu; R J Castellani; A Takeda; A Nunomura; C S Atwood; G Perry; M A Smith
Journal:  Mech Ageing Dev       Date:  2001-12       Impact factor: 5.432

4.  Ultrastructure of neurofibrillary tangles in Steele-Richardson-Olszewski syndrome.

Authors:  I Tellez-Nagel; H M Wiśniewski
Journal:  Arch Neurol       Date:  1973-11

5.  Diagnosis of Alzheimer's disease.

Authors:  Z S Khachaturian
Journal:  Arch Neurol       Date:  1985-11

6.  p38 kinase is activated in the Alzheimer's disease brain.

Authors:  K Hensley; R A Floyd; N Y Zheng; R Nael; K A Robinson; X Nguyen; Q N Pye; C A Stewart; J Geddes; W R Markesbery; E Patel; G V Johnson; G Bing
Journal:  J Neurochem       Date:  1999-05       Impact factor: 5.372

7.  Phosphorylated mitogen-activated protein kinase (MAPK/ERK-P), protein kinase of 38 kDa (p38-P), stress-activated protein kinase (SAPK/JNK-P), and calcium/calmodulin-dependent kinase II (CaM kinase II) are differentially expressed in tau deposits in neurons and glial cells in tauopathies.

Authors:  I Ferrer; R Blanco; M Carmona; B Puig
Journal:  J Neural Transm (Vienna)       Date:  2001       Impact factor: 3.575

8.  Activation of the JNK/p38 pathway occurs in diseases characterized by tau protein pathology and is related to tau phosphorylation but not to apoptosis.

Authors:  C Atzori; B Ghetti; R Piva; A N Srinivasan; P Zolo; M B Delisle; S S Mirra; A Migheli
Journal:  J Neuropathol Exp Neurol       Date:  2001-12       Impact factor: 3.685

9.  Neurons may live for decades with neurofibrillary tangles.

Authors:  R Morsch; W Simon; P D Coleman
Journal:  J Neuropathol Exp Neurol       Date:  1999-02       Impact factor: 3.685

Review 10.  A beta oligomers - a decade of discovery.

Authors:  Dominic M Walsh; Dennis J Selkoe
Journal:  J Neurochem       Date:  2007-02-05       Impact factor: 5.372

View more
  31 in total

Review 1.  Chronic effects of mild neurotrauma: putting the cart before the horse?

Authors:  Rudy J Castellani; George Perry; Grant L Iverson
Journal:  J Neuropathol Exp Neurol       Date:  2015-06       Impact factor: 3.685

Review 2.  Versatile somatic gene transfer for modeling neurodegenerative diseases.

Authors:  Ronald L Klein; David B Wang; Michael A King
Journal:  Neurotox Res       Date:  2009-08-11       Impact factor: 3.911

3.  Chronic traumatic encephalopathy: A paradigm in search of evidence?

Authors:  Rudy J Castellani
Journal:  Lab Invest       Date:  2015-04-13       Impact factor: 5.662

Review 4.  Biomarkers in Alzheimer's disease: past, present and future.

Authors:  Katarzyna Gustaw-Rothenberg; Alan Lerner; David J Bonda; Hyoung-gon Lee; Xiongwei Zhu; George Perry; Mark A Smith
Journal:  Biomark Med       Date:  2010-02       Impact factor: 2.851

Review 5.  Progress in Alzheimer's disease.

Authors:  Daniela Galimberti; Elio Scarpini
Journal:  J Neurol       Date:  2011-06-25       Impact factor: 4.849

Review 6.  The Amygdala as a Locus of Pathologic Misfolding in Neurodegenerative Diseases.

Authors:  Peter T Nelson; Erin L Abner; Ela Patel; Sonya Anderson; Donna M Wilcock; Richard J Kryscio; Linda J Van Eldik; Gregory A Jicha; Zsombor Gal; Ruth S Nelson; Bela G Nelson; Jozsef Gal; Md Tofial Azam; David W Fardo; Matthew D Cykowski
Journal:  J Neuropathol Exp Neurol       Date:  2018-01-01       Impact factor: 3.685

Review 7.  Cancer and Alzheimer's disease inverse relationship: an age-associated diverging derailment of shared pathways.

Authors:  Cristina Lanni; Mirco Masi; Marco Racchi; Stefano Govoni
Journal:  Mol Psychiatry       Date:  2020-05-07       Impact factor: 15.992

Review 8.  Neurodegenerative dementia and parkinsonism.

Authors:  A Gabelle; F Portet; C Berr; J Touchon
Journal:  J Nutr Health Aging       Date:  2010-01       Impact factor: 4.075

Review 9.  Understanding the roles of mutations in the amyloid precursor protein in Alzheimer disease.

Authors:  S Hunter; C Brayne
Journal:  Mol Psychiatry       Date:  2017-11-07       Impact factor: 15.992

10.  EFhd2 is a novel amyloid protein associated with pathological tau in Alzheimer's disease.

Authors:  Yancy Ferrer-Acosta; Eva N Rodríguez-Cruz; François Orange; Hector De Jesús-Cortés; Bismark Madera; Jaime Vaquer-Alicea; Juan Ballester; Maxime J-F Guinel; George S Bloom; Irving E Vega
Journal:  J Neurochem       Date:  2013-02-14       Impact factor: 5.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.